Frontotemporal Dementia
5 videos · last 6 months shuffled daily, then older videos newest first
▶
40:09 Next Steps After the Alector Trial in GRN FTD
Behavioral neurologist Dr. Chow explains for Cure GRN how clinical trials and endpoints work, what the completed Alector trial gave the GRN-related FTD field, what participants can learn after a trial and how to join a new one.
▶
39:17 FRF-001 Gene Therapy Trial Update, June 2026
The FOXG1 Research Foundation's gene therapy team updates the FOXG1 community on the first-in-human FRF-001 trial, covering how enrollment works, what happens at each stage and frequently asked questions.
▶
35:29 Elli Brimble on Natural History Data for ZTTK Research
Elli Brimble, Head of Clinical Strategy at Citizen Health, updates the ZTTK Citizen natural history study, now at 65 participants, and explains how FOXG1 data became a control for a placebo-free gene therapy trial, for the ZTTK SON-Shine Foundation.
▶
4:08 First Patient Dosed in FOXG1 Gene Therapy Trial
The FOXG1 Research Foundation announces that the first patient has received FRF-001, its investigational FOXG1 gene replacement therapy, in a first-in-human clinical trial the foundation sponsors.
▶
56:52 Alector Clinical Trial Results Townhall
AFTD's Penny Dacks and neurologist Carmela Tartaglia discuss the Phase 3 trial of Alector's latozinemab (AL001) in FTD-GRN, which did not affect clinical symptoms, and answer community questions.